Lexicon Pharmaceuticals Inc Asset Resilience Ratio
Lexicon Pharmaceuticals Inc asset resilience ratio. Lexicon Pharmaceuticals Inc (LXRX) has an Asset Resilience Ratio of 49.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LXRX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lexicon Pharmaceuticals Inc (1999–2025)
Asset resilience ratio of Lexicon Pharmaceuticals Inc from 1999 to 2025. This chart shows how Lexicon Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Lexicon Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lexicon Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Lexicon Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $132.57 Million | 49.32% |
| Total Liquid Assets | $132.57 Million | 49.32% |
Asset Resilience Insights
- Very High Liquidity: Lexicon Pharmaceuticals Inc maintains exceptional liquid asset reserves at 49.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lexicon Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Lexicon Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Lexicon Pharmaceuticals Inc Asset Resilience Ratio by Year (1999–2025)
Lexicon Pharmaceuticals Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Lexicon Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.46% | $61.90 Million | $184.99 Million | -23.94pp |
| 2024-12-31 | 57.40% | $171.30 Million | $298.42 Million | -6.91pp |
| 2023-12-31 | 64.32% | $147.56 Million | $229.43 Million | +16.96pp |
| 2022-12-31 | 47.36% | $92.01 Million | $194.30 Million | +30.79pp |
| 2021-12-31 | 16.56% | $22.68 Million | $136.91 Million | +3.80pp |
| 2020-12-31 | 12.76% | $26.01 Million | $203.79 Million | -43.63pp |
| 2019-12-31 | 56.39% | $235.55 Million | $417.71 Million | +28.35pp |
| 2018-12-31 | 28.04% | $79.67 Million | $284.14 Million | -29.03pp |
| 2017-12-31 | 57.07% | $249.13 Million | $436.54 Million | -5.99pp |
| 2016-12-31 | 63.05% | $299.90 Million | $475.62 Million | +14.44pp |
| 2015-12-31 | 48.62% | $318.36 Million | $654.83 Million | +5.75pp |
| 2014-12-31 | 42.87% | $202.07 Million | $471.38 Million | +9.45pp |
| 2013-12-31 | 33.42% | $91.63 Million | $274.16 Million | -18.43pp |
| 2012-12-31 | 51.85% | $192.78 Million | $371.78 Million | +29.70pp |
| 2011-12-31 | 22.16% | $95.38 Million | $430.51 Million | -22.52pp |
| 2010-12-31 | 44.67% | $163.90 Million | $366.88 Million | +20.64pp |
| 2009-12-31 | 24.04% | $61.96 Million | $257.76 Million | +17.45pp |
| 2008-12-31 | 6.59% | $17.24 Million | $261.51 Million | -57.27pp |
| 2007-12-31 | 63.86% | $235.84 Million | $369.30 Million | +37.70pp |
| 2006-12-31 | 26.16% | $49.77 Million | $190.27 Million | -9.38pp |
| 2005-12-31 | 35.54% | $77.72 Million | $218.71 Million | +1.13pp |
| 2004-12-31 | 34.41% | $72.95 Million | $211.98 Million | +26.63pp |
| 2003-12-31 | 7.78% | $22.12 Million | $284.20 Million | -19.10pp |
| 2002-12-31 | 26.89% | $54.25 Million | $201.77 Million | -28.70pp |
| 2001-12-31 | 55.58% | $133.39 Million | $239.99 Million | -19.12pp |
| 2000-12-31 | 74.71% | $164.87 Million | $220.69 Million | +42.87pp |
| 1999-12-31 | 31.84% | $7.10 Million | $22.30 Million | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more